Multiple Sclerosis Functional Composite (MSFC): Difference between revisions
Memoona Awan (talk | contribs) (reference purpose and technique) |
Memoona Awan (talk | contribs) (reference) |
||
| Line 12: | Line 12: | ||
# Hand Function | # Hand Function | ||
# Cognitive function | # Cognitive function | ||
Performed with in 20 minutes. | |||
Hand function is tested with the nine-hole peg test<ref name=":1" />. | |||
PASAT was originally included to cover the cognitive dain. It measures processing speed and working memory, both of which are frequently affected functions in MS patients<ref name=":1" />. | |||
Ambulatory function is tested with the timed 25-foot walk test (T25W). The T25W is a reliable test for patients with more severe gait impairment, because it primarily assesses walking speed<ref name=":1" />. | |||
The results of the tests that assess these domains are depicted in an interval scale (seconds or number of correct responses) and can be converted to a ''Z'' score that is based on values of a reference population | |||
The results of the tests that assess these domains are depicted in an interval scale (seconds or number of correct responses) and can be converted to a ''Z'' score that is based on values of a reference population. An overall score can be calculated by averaging the ''Z'' score of the subtests<ref name=":1" />. | |||
==Evidence== | ==Evidence== | ||
has good intra- and inter-rater reliability and it results in a score on a continuous scale. The MSFC has been used as the primary outcome in a treatment trial in SPMS [<nowiki/>[[/www.ncbi.nlm.nih.gov/pmc/articles/PMC5336539/#CR49|49]]]. While MSFC progression was slowed, treatment effects were not observed with the EDSS. If the components are applied in a sensible way, the MSFC may be used as the primary endpoint in future clinical trials. | |||
==Resources== | ==Resources== | ||
Revision as of 19:07, 2 March 2024
Purpose[edit | edit source]
The Multiple Sclerosis Functional Composite (MSFC) designed by "National MS Society's Clinical Outcome Assessment Task" and is a standardized tool used to quantify degree of disability in patients with multiple sclerosis (MS)[1]. Limitations in EDSS leads to development of MSFC in the early 1990's, to improve clinical assessment of patients with multiple sclerosis[2][3]. The traditional scales such as EDSS scale are inadequate in measuring some key aspects of MS for example cognitive function and have psychometric limitations as well[1].
Technique[edit | edit source]
MSFC covers three functional domains[3]:
- Ambulatory Function
- Hand Function
- Cognitive function
Performed with in 20 minutes.
Hand function is tested with the nine-hole peg test[3].
PASAT was originally included to cover the cognitive dain. It measures processing speed and working memory, both of which are frequently affected functions in MS patients[3].
Ambulatory function is tested with the timed 25-foot walk test (T25W). The T25W is a reliable test for patients with more severe gait impairment, because it primarily assesses walking speed[3].
The results of the tests that assess these domains are depicted in an interval scale (seconds or number of correct responses) and can be converted to a Z score that is based on values of a reference population. An overall score can be calculated by averaging the Z score of the subtests[3].
Evidence[edit | edit source]
has good intra- and inter-rater reliability and it results in a score on a continuous scale. The MSFC has been used as the primary outcome in a treatment trial in SPMS [49]. While MSFC progression was slowed, treatment effects were not observed with the EDSS. If the components are applied in a sensible way, the MSFC may be used as the primary endpoint in future clinical trials.
Resources[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 JS, RA, GR, SC. F Rudick, Cutter, Reingold. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Multiple Sclerosis Journal [Internet]. 1999 [cited 2024 Mar 1];5(4):244–250.
- ↑ Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, . Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain [Internet]. 1999 [cited 2024 Mar 1];122(5):871–882.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Van Munster, C. E., & Uitdehaag, B. M. Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS drugs. 2017;31(3):217–236.
